Effect of Bovine Milk Fat-based Infant Formulae on Microbiota, Metabolites and Stool Parameters in Healthy Term Infants in A Randomized, Crossover, Placebo-controlled Trial

Ellen Looijesteijn (✉ Ellen.Looijesteijn@frieslandcampina.com)

FrieslandCampina

Rutger W. W. Brouwer

Erasmus MC

Ruud J. W. Schoemaker

FrieslandCampina

Laurien H. Ulfman

FrieslandCampina

Stephanie L. Ham

Metabolon Inc

Prescilla Jeurink

FrieslandCampina

Eva Karaglani

Harokopio University

Wilfred F. J. IJcken

Erasmus MC

Yannis Manios

Harokopio University

Research Article

Keywords: Milk Fat, Microbiota, Deep sequencing, Faecal metabolites, SN-2-palmitate, Calcium excretion, Stool consistency, Faecal soap

Posted Date: February 8th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1280415/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: Natural enrichment of sn-2 palmitate content of infant formulae by using bovine milk fat is known to reduce faecal fatty acid soap formation and improve stool consistency, but effects on gut microbiota composition are unknown. The purpose of this study was to test the influence of milk fat-based formula high in sn-2 palmitate on the infants' gut microbiota composition and to confirm the beneficial effects of the formula on faecal composition and stool consistency.

Methods: Twenty-two healthy term, formula-fed infants were enrolled in a single-blinded randomized, crossover, placebo-controlled trial. After a 2 week run in period, infants received either a 50% milk fat-based formula containing 39% sn-2 palmitate (MF) or a vegetable fat-based formula (VF) containing 10% sn-2 palmitate in a 2x2 week crossover design. Faecal microbiota composition was the primary outcome of the study. Other outcomes included faecal fatty acid soap excretion, calcium excretion, gut comfort parameters and faecal metabolites.

Results: Microbiota analysis showed that bifidobacteria dominated the gut microbiota of most infants. Neither alpha- nor beta-diversity was significantly influenced by the intervention. The MF formula resulted in significantly lower faecal levels of palmitic acid soap and total fatty acid soaps than the VF formula ($p < 0.0002$). Additionally, calcium excretion and palmitic acid concentration were significantly ($p < 0.05$) lower in stool samples after MF intervention. Furthermore, a significant physiological effect on softer stools was observed in the MF intervention compared to the VF intervention ($p = 0.02$). Of the 870 measured faecal metabolites, 263 were significantly different after MF and VF intervention ($p < 0.05$). Most of these were found at higher levels after MF intervention, potentially indicative of the complex structure of milk fat. Metabolites with more than 2-fold change between interventions were mostly lipid-derived and included several milk fat-specific fatty acids.

Conclusions: Replacing part of the vegetable fat in infant formula with bovine milk fat with high sn-2 palmitate levels did not change the microbiota composition, although a reduction in faecal palmitate soaps, total fatty acid soaps and calcium excretion while improving stool consistency in the MF intervention was confirmed. In addition, 263 faecal metabolites were significantly different, many related to the fat source.

Trial registration: Netherlands Trial Registry Identifier: NL7815 19/06/2019

Background

Human milk is designed by nature and is the best nutrition for healthy growth and development of babies. The fat fraction of human milk is particularly important for a developing infant. It delivers a large part of the required energy as well as essential fatty acids, fat-soluble vitamins and other bioactive components, such as phospholipids and cholesterol (1). Most of the human milk fat fraction comprises triglycerides with a specific distribution of the fatty acids over the glycerol backbone that facilitates absorption. Palmitic acid (C16:0) is the most common long-chain saturated fatty acid (LCSFA) in human

milk, and 70-88% of all C16:0 is esterified at the sn-2 position (2). At this position, LCSFAs are easily absorbed during digestion in the form of monoglycerides. In contrast, LCSFAs esterified at the sn-1 or sn-3 positions, liberated from the glycerol backbone by pancreatic lipases during digestion, are poorly absorbed because of their low water solubility. Consequently, complexes with calcium can be formed, resulting in calcium soaps that are excreted in the faeces (1).

Vegetable fat blends are often used as fat sources in infant formulae (IF). However, commonly used fat blends contain only 10-20% C16:0 at the sn-2 position. The remaining 80-90% C16:0 esterified at the sn-1 and sn-3 positions in triglycerides increases the risk of soap formation. In addition to reduction of fat and calcium absorption, this is undesired because of the association with hard stools and constipation in infants (2). To meet infant requirements and prevent soap formation, fat blends used for IF should preferably be as close as possible to human milk fat with respect to both fatty acid composition and its distribution over triglycerides. Bovine milk fat composition contains 40-45% of C16:0 at the sn-2 position, resembling human milk fat structure better than most vegetable fats (2,3). Recently, the similarity index has been developed as a tool to design the optimal composition of fat blends (4). Indeed, an infant formula with a mixed fat blend of selected vegetable oils and bovine milk fat (50%) reduced faecal soap formation and improved stool consistency compared to a standard IF with 100% vegetable fat in a recent clinical study (5). In addition to an effect on stool consistency, faecal soaps might also influence gut microbiota composition and activity. *In vitro*, calcium palmitate inhibited the growth of the beneficial bacteria *Faecalibacterium prausnitzii* and several *Bifidobacterium* species (6). Furthermore, several clinical trials demonstrated higher faecal concentrations of bifidobacteria in infants fed with IF rich in sn-2 palmitate than in infants fed with IF low in sn-2 palmitate (7–9). In these trials, vegetable fat in the form of palm oil was used, which was chemically structured (inter-esterified) to enrich the sn-2 palmitate content of the IF.

The effect of IF differing in sn-2 content by partly replacing the fat source with bovine milk fat on gut microbiota composition and activity is largely unknown. The objective of the current study was to compare IF with a mixed fat blend of 50% vegetable oils and 50% bovine milk fat, containing 39% sn2-palmitate, with a standard formula with the same total fat content but originating from a 100% vegetable fat blend containing 10.1% sn2-palmitate. The primary outcome parameter was faecal microbiota composition, the secondary outcomes were faecal palmitic acid soap, faecal free palmitic acid, total faecal fatty acid (soaps), faecal calcium excretion, stool characteristics and gut comfort and, additional outcomes included faecal metabolites.

Methods

Study design and population

The clinical trial was a single-blinded, crossover, randomized, placebo-controlled study conducted with healthy, full-term, exclusively IF-fed infants. The total duration of the study was 6 weeks, including a 2-week run-in period during which the infants consumed standard IF with a 100% vegetable fat source (VF).

Infants were enrolled in the study during routine visits to the study pediatricians. Upon inclusion in the study, the randomization was performed centrally, at Harokopio University, by a designated research assistant who assigned the participants to the treatment arms. Upon enrolment, the infants were alternately allocated to consume the VF formula or a test formula with 50% milk fat and 50% vegetable fat (MF) in a 2 x 2 week crossover design after the run-in period (Figure 1). The parents, paediatricians and statisticians were blinded to the IF. The study was approved by the ethics committee of Harokopio University (Athens, Greece) and was conducted between May 2019 (first subject in) and November 2019 (last subject out) in Athens, Greece. The trial was conducted in agreement with the International Conference on Harmonisation guidelines on Good Clinical Practice and was registered at the Dutch Trial Register ([trialregister.nl](https://www.trialregister.nl)) as NL7815.

Infants were recruited during routine visits to their private paediatricians. They were enrolled at 9-16 weeks of age. Infants were eligible for inclusion when they were healthy, full-term (gestational age ≥ 37 weeks) with a birth weight between the 10th and 90th percentiles, and exclusively formula-fed at least two weeks before enrolment and during the entire study. Complementary feeding was initiated only after the endpoint measurements. Exclusion criteria included severe acquired or congenital diseases, mental or physical disorders, any symptoms of allergy, parents or siblings with documented cow's milk allergy, use of probiotics, antibiotics or other medication that treat or cause gastrointestinal symptoms, use of medication known or suspected to affect fat digestion, absorption and/or metabolism, such as nutritional supplements, suppositories, medication that may suppress or neutralize gastric acid secretion and gut motility and participation in another clinical trial. Written informed parental consent was obtained for each infant from both parents. In total, 22 infants were enrolled in the study.

Primary outcome of the study was defined as a difference in intestinal microbiota composition between MF and VF intervention. Secondary outcomes of the study were defined as a decrease in faecal excretion of fatty acid soaps and calcium by the MF intervention and improved gut comfort parameters in the MF intervention.

Study formulae and formula consumption

Two different IF were compared in the study: standard IF with a 100% vegetable fat source (VF) and test formula with 50% milk fat and 50% vegetable fat (MF). The nutritional composition of the two study products was similar regarding macronutrients, with the only difference being their fatty acid profiles and percentage of sn-2 palmitate (Table 1). Both IF complied with the compositional requirements laid down in Directive 2006/141/EC. The products were identical to IF used in a previously published study (5). The products were produced by FrieslandCampina in the Netherlands and were packed in similar tins of 400 g. Instructions for the parents/caregivers on daily volume of formula intake were given on the labels of the tins. The parents/caregivers recorded formula consumption (timing, frequency and exact volume) in a diary during the last three consecutive days of the run-in period and the two intervention periods. Additionally, the study personnel collected all formula tins to monitor compliance and formula consumption.

Table 1 Macronutrient, fatty acid and calcium composition of infant formulae

Nutrient/Ingredient	VF	MF
Energy (kcal/100 ml)	66	66
Intact protein (g/100 ml)	1.4	1.4
Carbohydrates (g/100 ml)	7.0	7.1
Galacto-oligosaccharides (g/100 ml)	0.27	0.27
Fat (g/100 ml)	3.5	3.5
<i>Fatty acids; mol% of TAGs</i>		
C12:0; Lauric acid	10.4	6.0
C14:0; Myristic acid	3.9	7.4
C16:0; Palmitic acid	24.9	18.9
C18:0; Stearic acid	3.4	5.2
C18:1; Oleic acid	39.0	36.9
C18:2; Linoleic acid	12.7	11.7
C18:3; α -Linolenic	1.8	1.5
C20:0; Arachidic acid	0.3	0.2
% C16:0 in sn-2 position	10.1	39
Calcium (mg/100 ml)	56	53

VF: standard formula with 100% vegetable fat source; MF: test formula with 50% milk fat.

Stool collection

Parents collected stool samples of ~30 g during the last three days (days 12-14) of the run-in period and each of the two intervention periods following a previously described procedure (5). The frozen samples were shipped in dry ice to Eurofins Laboratories, Madison, Wisconsin, USA, to analyse the fat composition and calcium concentration as described previously (5).

DNA isolation, library preparation and sequencing

DNA was isolated from lyophilized faecal material using the QIAamp Fast DNA Stool Mini Kit (QIAGEN, Venlo, The Netherlands) according to the manufacturer's instructions. Isolated DNA samples were quantified using the Quantit method (Thermo Fisher Scientific). Fifty nanograms of DNA was used to generate dual-indexed sequencing libraries according to the DNA Flex method (Illumina) using 5 PCR

amplification cycles. The resulting libraries were sequenced on Illumina HiSeq2500 sequencers (Illumina) according to the manufacturer's instructions. Paired-end reads were generated of 300 base pairs in length using an in-house developed sequencing protocol. Between 20-24 M reads were generated per sample.

Illumina adapters were removed from the paired-end reads using AdapterTrimmer (<https://github.com/erasmus-center-for-biomics/AdapterTrimmer>), and the remainder was processed using MetaPhlan version 3.0.6 using the CHOCOPhlan reference (version 201901) (10). This analysis identified the microbial composition of the samples up to the species level and served as input for the downstream analysis. Downstream analysis was performed using the phyloseq package in R (version 4.1.1)(11).

Metabolomics

Metabolon (Morrisville, North Carolina, USA) performed the metabolite analysis using the HD4 Platform. Lyophilized faecal samples were extracted with methanol to precipitate protein and dissociate small molecules bound to protein or trapped in the precipitated protein matrix, followed by centrifugation to recover chemically diverse metabolites. The resulting extract was divided into fractions. These were used for analysis by two separate reverse phase (RP)/UPLC-MS/MS methods using positive ion mode electrospray ionization (ESI), for analysis by RP/UPLC-MS/MS using negative ion mode ESI and for analysis by HILIC/UPLC-MS/MS using negative ion mode ESI. Metabolon's peak identification software was used to match ions to a library of standards for metabolite identification and for metabolite quantitation by peak area integration.

Gut comfort, stool consistency and anthropometric measurements

During home visits after the run-in period and the two intervention periods, research assistants completed the "Questionnaire on Paediatric Gastrointestinal Symptoms" (QPGS-RIII infant/toddler) (12) together with the parents. This assessed overall gut comfort and the incidence of minor digestive issues, such as vomiting, regurgitation, colic, constipation, diarrhoea and crying episodes. Parents used the "Amsterdam Infant Stool Scale" (AISS) (13) to assess consistency (four categories: watery, soft, formed and hard), amount/volume (smear to more than 50% of the nappy's surface) and colour (six categories) of stools during the run-in period and both intervention periods. This was done during the same three days as stool collection. Infant body weight and length were measured during scheduled visits at study locations at the end of the three two-week periods.

Safety

Adverse events (AEs) and serious adverse events (SAEs) were recorded throughout the study and monitored by an independent pediatrician. No code-break requests occurred for AEs or SAEs throughout the study. One adverse event was reported during the study, diarrhea during the run-in period, and this infant discontinued the study (see Figure 1).

Statistical analysis

Statistical analyses on the primary outcome, microbial composition, included alpha and beta diversity, MDS visualisation, as well as ANOVA and Kruskal-Wallis rank sum tests. To determine whether the interventions affected the microbial diversity in the infants, both the Shannon alpha diversity and Bray-Curtis beta diversity were determined via the phyloseq R package (11) using standard parameters. Multidimensional scaling (MDS) was used to visualize the beta diversity. Subsequently, ANOVA via the aov function in R was used to determine associations between the axes along the MDS plot and registered clinical factors of the subjects. Clustering was performed on the Bray-Curtis beta-diversity using hierarchical clustering with the ward. D2 linkage method as available in R. The microbes differentially present in the clusters were determined using Kruskal-Wallis rank sum tests. The analysis scripts are available on GitHub (<https://github.com/erasmus-center-for-biomics/bamboo-study-R>). In addition, the microbes were also analyzed in R according to the methodology described below for the biochemical measurements and clinical outcomes.

The biochemical measurements of the faecal samples and clinical outcomes were analysed by 4Pharma Ltd. (Finland) using SAS® version 9.4 for Windows (SAS Institute Inc., Cary, NC, USA). For all endpoints, a *p*-value less than 0.05 was considered statistically significant.

An ANOVA model appropriate for a 2 × 2 crossover design was used to assess mean differences between treatments for the different parameters. When the normality assumption was not met, variables were log-transformed, or the Wilcoxon signed-rank test was applied. The statistical model included treatment, sequence and period as fixed effects and subject (sequence) and residual error terms as random effects. All statistical tests were two-sided and performed with $\alpha = 0.05$. Missing values were not imputed in the analyses. Demographics, birth history, feeding habits, family socio-demographics, medical history, concomitant treatments, and baseline QPGS-RIII questionnaire were summarized using descriptive statistics for continuous variables and counts and percentages for categorical variables. Ordinal variables were assessed with a repeated measures cumulative logit model.

Metabolon (Morrisville, North Carolina, USA) used crossover ANOVA to statistically analyse the metabolite data. For all analyses, missing values, if any, were imputed with the observed minimum for that particular compound. The statistical analyses were performed on natural log-transformed data. To determine which metabolites made the largest contribution to the classification, RFA was performed (14) based on the computed "Mean Decrease Accuracy" (MDA) using the "randomForest" R package (15). The MDA was determined by randomly permuting a metabolite, running the observed values through the trees, and then reassessing the prediction accuracy. The values of the metabolite are permuted for the out-of-bag (OOB) samples for each tree. The classification accuracy for each of these trees was compared to the original classification error. These differences were averaged across all trees and re-scaled based on the standard deviation of these (and number of trees).

Results

Study population

Twenty-two infants were enrolled in the study, of which 19 completed the study. Three infants discontinued during/after the run-in period because of either diarrhoea (1), disliking the formula (1) or failure to deliver data and samples (1) (Figure 1). Complete datasets were obtained for 16 infants, 7 in the VF-MF group and 9 in the MF-VF group. For one infant in each of the groups, no faecal samples were obtained in the second intervention period, and for that reason, faecal samples of these infants were not analysed. For another infant in the VF-MF group, questionnaires and biochemical analysis of the faecal samples were lacking. Additional file 1, Supplementary Table 1 gives an overview of IF allocation and availability of data per subject.

The baseline and family characteristics of the infants are described in Table 2. Weight at birth, gestational age and infants' age and weight at inclusion were similar among the groups.

Table 2 Baseline and family characteristics of the study subjects

	MF-VF (n=10)	VF-MF (n=9)
Gender, n (%)		
Female	5 (50.0)	4 (44.4)
Male	5 (50.0)	5 (55.6)
Age at screening, days		
Mean (SD)	92.0 (11.6)	89.4 (14.6)
Median	89	84
Min-max	70-112	67-111
Ethnicity, n (%)		
Albanian	1 (10.0)	1 (11.1)
Greek	9 (90.0)	8 (89.9)
Length at birth, cm		
Mean (SD)	49.4 (2.0)	50.2 (1.5)
Median	50.0	50.0
Min-max	44.0-51.0	49.0-54.0
Weight at birth, g		
Mean (SD)	3063.0 (372.8)	2935.0 (265.0)
Median	3150.0	2910.0
Min-max	2500-3480	2500-3455
Gestational age, weeks		
Mean (SD)	37.7 (0.8)	38.6 (0.5)
Median	37.5	39.0
Min-max	37-39	38-39
Mode of delivery, n (%)		
C-section	8 (80.0)	6 (66.7)
Natural delivery	2 (20.0)	3 (33.3)
Length at screening, cm		
Mean (SD)	62.05 (2.2)	62.1 (3.1)

Median	61.5	61.5
Min-max	59.0-65.3	58-68
Weight at screening, g		
Mean (SD)	5963.7 (601.2)	5827.1 (945.9)
Median	5958.5	6180
Min-max	4860.0-7083.0	4130-7200

VF: standard formula with 100% vegetable fat source; MF: test formula with 50% milk fat; SD: standard deviation.

MF-VF: crossover group with MF first; VF-MF: crossover group with VF first

Formula consumption and anthropometric data

The average weekly milk intake and the infants' weight and length development during the study were similar for the MF-VF and VF-MF groups (Additional file 1, Supplementary Table 2).

Microbiota analysis

The faecal microbial profiles for most infants (13 out of 17 infants, 76%) were dominated by the genus *Bifidobacterium* and in line with previous reports (16,17). The microbiota of the other infants were dominated by *Klebsiella* (3 children) and *Escherichia* (1 child). Through the intervention, changes in the microbial profiles were observed. However, the variation in the microbiome between the infants was larger than the effect of the intervention (Figure 2). Furthermore, no specific clades were directly and significantly affected by the interventions performed in this study. We performed a basic univariate analysis on each separate type of the 250 different species, where only *Enterococcus faecalis* was significant before multiple testing ($p < 0.02$), though not after multiple testing correction, due to the high number of species tested and relatively low sample size.

To determine whether the interventions affected the microbial diversity in the infants, both the Shannon alpha diversities and Bray-Curtis beta diversities were determined; however, neither of these methods showed an intervention-specific effect.

Multidimensional scaling (MDS) analysis identified three beta diverse distinct groups, also found with hierarchical clustering (Figure 3). These sample groups do not correspond to the time of sampling or interventions. With few exceptions, the samples from singular infants localize together. Of the abundant microbes, the relative proportion in the samples of the genera *Aeriscardovia*, consisting only of the species *Aeriscardovia aeriphila* that was formerly known as *Bifidobacterium aerophilum* (adjusted p -value $2.4E-3$) and *Klebsiella* (adjusted p -value $9.4E-6$), primarily differentiate group 1 from 2 and 3. In addition, group 2 can be differentiated from groups 1 and 3 by their, albeit very low ($<0.08\%$), relative

abundance of *Thermoleophilum* (adjusted p -value 8.1E-6), a genus of the phylum Actinobacteria. In total, the relative abundances of 16 genera were significantly different between the 3 clusters. Using Pearson's chi square tests, the clusters were compared to infant-specific categorical clinical parameters. Clusters were significantly associated with gender, prior breastfeeding and stool frequency (Table 3). Group 3 was enriched for males, and group 2 was enriched for breastfed infants.

The three groups, determined by hierarchical clustering, are indicated by gray ovals. The shapes indicate the sexes male (circle) or female (triangle), while the colours indicate absence (blue) or presence (red) of prior breastfeeding before the start of the trial.

Table 3 Clinical parameters significantly associated with beta diversity.

Parameter	p -value	Adjusted p -value (FDR)
Gender ^P	0.007	0.034
Prior Breastfeeding ^P	0.001	0.009
Mode of delivery ^P	0.852	0.852
Bowel frequency ^P	0.063	0.190
Stool consistency ^P	0.191	0.344
Stool colour ^P	0.305	0.457
Stool amount ^P	0.486	0.546
Formula volume consumed ^k	0.433	0.546
Stool frequency (day 12-14) ^k	0.172	0.344

Analysis based on Pearson's chi-squared tests (p) or Kruskal-Wallis rank sum tests (k); FDR: false discovery rate

Stool fatty acids, fatty acid soaps and calcium concentration

The results of the main biochemical measurements of stool samples are shown in Table 4. The IF used in the current study strongly influenced the formation of faecal palmitic acid soap and total fatty acid soap concentrations. The MF formula with a higher level of sn2-palmitate resulted in significantly lower faecal levels of palmitic acid soap and total fatty acid soaps than the VF formula ($p < 0.0002$), as illustrated in Figure 4. Concomitantly, calcium excretion and palmitic acid concentration were significantly ($p < 0.05$) reduced in stool samples after the MF intervention. No significant difference was noted for the total free fatty acid concentration. For faecal palmitic acid soap, the concentration as well as the proportion palmitic acid soap of total faecal soaps were significantly different between groups.

Table 4 Mean stool fatty acids, fatty acid soaps and calcium composition (mg/g stool dry weight)

Variable	Run-in VF (n=16)	Intervention MF (n=16)	Intervention VF (n=16)	<i>p</i> -value intervention
Palmitic acid soap (SD), mg/g	214.3 (36.6)	133.5 (44.9)	206.2 (33.9)	0.0002
Palmitic acid soap (SD), %	74.2 (3.4)	58.9 (9.5)	73.4 (6.6)	0.0003
Palmitic acid (SD), mg/g	9.7 (13.1)	3.8 (4.6)	5.2 (6.3)	0.0335
Palmitic acid (SD), %	34.3 (12.4)	26.3 (12.1)	29.1 (12.7)	0.3409
Calcium excretion (SD), mg/g	47.4 (6.7)	44.4 (7.9)	47.7 (6.5)	0.0335
Total fatty acid soaps (SD), mg/g	288.6 (47.1)	222.7 (47.3)	281.9 (43.8)	0.0001
Total free fatty acids (SD), mg/g	24.1 (24.8)	14.4 (12.5)	16.4 (10.3)	0.3016

VF: standard formula with 100% vegetable fat source; MF: test formula with 50% milk fat; SD: standard deviation.

Stool consistency and gut comfort

Figure 5 shows the distribution of the ordinal stool consistency scores for the VF and MF interventions. The stool consistency scores, according to AISS, showed a *p*-value of 0.02 for the intervention fixed effect test, where the odds ratio for intervention difference was 4.0 (95% CL: 1.2-13.2). This implies that stool samples generally have a lower rank on the (ordinal) AISS scale in the MF intervention, i.e. altering the stool composition towards softer stools. AISS assigns one of four categories to an infants' stool: Watery, Soft, Formed and Hard. The latter category, however, was not assigned to any faecal sample.

There was no significant difference for vomiting, regurgitation, colic, constipation, diarrhoea and crying episodes between groups based on the QPGS-RIII infant/toddler. Additionally, no difference in stool volume or stool colour based on AISS was observed (data not shown).

Metabolite analysis

In total, 870 metabolites were measured in the faecal samples (see Additional file 2), of which 263 were significantly different between the MF and VF interventions determined by a crossover ANOVA ($p < 0.05$). The majority of these 263 metabolites were found to be higher in the faeces following MF intervention, potentially indicative of the complex composition of milk fat (18). The significantly affected metabolites (45) with at least a 2-fold change between interventions are indicated in Figure 6. Most of these are lipid-derived, but some are metabolites from vitamin, amino acid and nucleotide metabolism. Higher levels of

faecal metabolites after MF intervention include molecules of known milk fat origin: margarate, 12/13-methylmyristate, pentadecanoate, pristanate, phytanate, docosapentaenoate, 14/15-methylpalmitate, docosadienoate, palmitoleate and carotene diol. Furthermore, several other lipid-derived molecules, fucitol, 3-aminoisobutyrate, 3-indoleglyoxylic acid, N-carboxymethylalanine, N-methylproline and several forms of vitamin E (tocopherols), were found at levels that were at least 2-fold higher after MF intervention than after VF intervention. In contrast, significantly influenced metabolites higher after VF intervention included tocotrienols, which are other forms of vitamin E. The different forms of vitamin E measured in faeces after either MF or VF intervention are consistent with the composition of the IF consumed, as tocotrienols are more abundant in the vegetable fat blend used for the VF formula than tocopherols. Several metabolites related to polyphenol metabolism (2-hydroxyhippurate, hippurate, and cinnamoylglycin) were also higher after VF intervention, which could result from the higher levels of polyphenols in the vegetable fat blend (high in palm oil) included in the VF formula. For other metabolites higher after VF intervention (gamma-amino butyric acid (GABA), phenethylamine, agmatine, N-carbamoyl putrescine, and nicotinate ribonucleoside), no direct link with the compositions of the study products is suspected, and these metabolites might thus reflect a treatment effect.

Coloured dots indicate significantly different ($p < 0.05$) metabolites with at least a two-fold change between MF and VF intervention (upper left corner: higher in VF intervention; upper right corner: higher in MF intervention).

Random forest analysis (Additional file 1, supplementary Figure 1) shows that the two intervention groups can be distinguished from their metabolite profile with a predictive accuracy of 91%. In addition, it provides the metabolites that are most predictive of the type of intervention. These metabolites partly overlap with the metabolites shown in Figure 6, but in addition several carnitines, ergosterol, 7-ketocholesterol, lyxonate, myristate and laurate helped to distinguish both groups.

Discussion

Faecal palmitate soap and stool consistency

Beta-diversity analysis of microbiota composition separated the faecal samples into three different groups that were not related to the intervention. Important clinical parameters associated with the group separation were prior breastfeeding and gender. The lasting effects of breastfeeding on gut microbiota composition are well known (26). The relationship between gender and microbiota composition has not been thoroughly studied, although gender differences in microbiota have been observed in several studies (27,28). We did not perform measurements before the run-in period, but it is likely that the differences in gut microbiota composition detected by beta-diversity analysis were already present before the start of the trial.

Faecal metabolites

Despite the absence of apparent effects of the study formulae on microbiota composition, approximately 30% of the 870 faecal metabolites measured were significantly different between the VF and MF interventions. Several metabolites with the highest fold changes reflected differences in concentrations of these molecules in the formulae, such as milk fat-specific fatty acids and different forms of vitamin E. The odd chain fatty acids pentadecanoate (C15) and margarate (C17) have been used in various studies as serum and adipose tissue markers of dairy fat intake (29). In agreement with that, our results demonstrate higher levels of these markers in faeces after MF intervention. Branched chain fatty acids (BCFAs) found elevated after MF intervention, such as 14/15-methylpalmitate, 12/13-methylmyristate, pristanate and phytanate, are also directly derived from milk fat (30). Increased faecal levels of BCFAs could be beneficial, as based on *in vitro* work, it is assumed that BCFAs are important for the growth and metabolism of enterocytes (31) and reduce inflammatory markers (32). Additionally, palmitoleate, another milk fat-specific fatty acid that increased after MF intervention, may be associated with several health benefits, such as favourable metabolic health outcomes (33).

Further differences between interventions were found for several microbial metabolites of polyphenolic compounds. This can be explained by the levels of polyphenols in palm oil (34), which formed a significant part of the vegetable fat source of the VF formula. In addition, differences were detected in the levels of microbial compounds that could not be linked to the composition, such as GABA. GABA is an important inhibitory neurotransmitter that can be produced by several bacteria, such as *Bifidobacterium*, *Bacteroides* and *Escherichia* species (35,36), and can also be consumed by several gut bacteria (35). GABA levels were significantly lower in the MF intervention, but we could not detect a correlation between specific microbial species and faecal GABA levels. This is in contrast to the study of Altaib et al (36) that showed significant separation between samples high and low in GABA through beta-diversity analysis of the microbiota. In our MDS plots, samples of subjects clustered together despite large differences in GABA content. Although we did not find a relation between GABA levels and specific microbial species or overall microbiota composition, we cannot exclude the possibility that the difference in GABA is caused by microbial activity. GABA synthesis is highly strain dependent (37), and differences in strain content were not determined. Hypothetically, differences might also be caused by a difference in absorption of GABA from the gut, but as no serum levels of this metabolite were measured, this remains inconclusive and requires further investigation.

We did not include a breast milk-fed control group in our study. We do, however, expect that the metabolic profile of breastfed infants is more similar to that after MF intervention than after VF intervention, as bovine milk fat more closely resembles human milk fat than vegetable fat blends (2). To the best of our knowledge, studies directly comparing faecal metabolites of breastfed infants and milk fat-based formula-fed infants have not yet been reported.

Conclusions

In summary, this study confirms the beneficial effects of replacing vegetable fat with milk fat in infant formula by improved stool consistency and lower faecal soap formation. However, no significant

differences in stool microbiota composition were observed between the nutritional interventions, possibly due to the presence of GOS in both formulae. In addition, metabolites were significantly different between the intervention groups. Whether these differences are merely the representation of the different fat blends and/or drive the clinical differences remains to be explored.

Abbreviations

AE: adverse events; AISS: Amsterdam Infant Stool Scale; BCFAs: branched chain fatty acids; BF: breastfed; C16:0: palmitic acid; FF: formula-fed; GABA: gamma-amino butyric acid, GOS: galacto-oligosaccharides; HM: human milk; HMO: human milk oligosaccharides; IF: infant formula; LCSFA: long chain saturated fatty acid; MDA: mean decrease accuracy; MF: milk fat-based formula with 50% milk fat; PA: palmitic acid; RFA: random forest analysis; SAE: serious adverse events; TAG: triacylglycerol; VF: vegetable fat-based formula with 100% vegetable fat source; QPGS-RIII: Questionnaire on Paediatric Gastrointestinal Symptoms-Rome III

Declarations

Ethics approval and consent to participate

The study was performed in accordance with the current version of the Declaration of Helsinki (64th WMA General Assembly, Fortaleza, Brazil, October 2013). The trial was conducted in agreement with the International Conference on Harmonisation (ICH) guidelines on Good Clinical Practise (GCP).

All participating parents (both mothers and fathers) provided written informed consent for the participation of their infants in the study prior to being screened. The parental information letter detailed the procedures of the study (aim, methodology, measurements, etc.) and the paediatricians explained them to parents who expressed interest in the study. The parents were then given sufficient time ($\pm$ one week) to consider the information before signing and dating the informed consent form, indicating that they fully understood the information, and willingly volunteered to participate in the study. The participating parents were given a copy of the informed consent form for their information. The original copy of the informed consent was kept in a confidential file in the Principal Investigator's central records.

Consent for publication

Not applicable.

Availability of data and materials

The dataset supporting the conclusions of this article is available in the Bioproject repository, PRJNA798191, <https://www.ncbi.nlm.nih.gov/bioproject/798191>. The trial protocol is available from the corresponding author upon reasonable request.

Competing interests

EL, RS, LU are, and PJ was, employed by FrieslandCampina. The other authors report no conflicts of interest.

SLH is an employee at Metabolon, Inc. and, as such, has affiliations with or financial involvement with Metabolon, Inc.

Funding

The present study was funded by FrieslandCampina Nederland B.V. and is part of an Agri and Food Public Private Partnership, project TKI-AF18142 entitled Combining deep sequencing omics approaches to translate an altered microbial composition towards health benefits. FrieslandCampina was involved in the design of the study, interpreting the data and writing the manuscript. FrieslandCampina was not involved in the recruitment of participants, data collection, management or analysis of clinical outcomes.

Authors' contributions

YM, EK and PJ developed the study design and protocol. YM and EK were responsible for the overall conduct of the study, quality control in the field, and clinical data interpretation and drafted the corresponding tables and figures. YM was the Principal Investigator and is the overall guarantor. EL, RBr, RS and WIJ analysed the microbiota data and drafted the corresponding figures. EL, RS and SH analysed the metabolite data and drafted the corresponding figures. EL, LU, RS, WIJ and RBr wrote the first draft of the manuscript. All authors contributed to interpretation of the data and provided critical comments to the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to thank all the participants for their willingness to participate in the study. The authors also thank the study team for their valuable help in the study, 4Pharma for statistical support and Eurofins for faecal sample analysis. The authors would also like to express their gratitude to Corrie Jansen for DNA extraction from faecal samples, Arjen Nauta and Loo Wee Chia for contributing to the interpretation of microbiota data and TKI consortium members of HorAlzon B.V. for valuable input in discussions.

References

1. Koletzko B. Human milk lipids. *Ann Nutr Metab.* 2017;69(2):28–40.
2. Hageman JHJ, Danielsen M, Nieuwenhuizen AG, Feitsma AL, Dalsgaard TK. Comparison of bovine milk fat and vegetable fat for infant formula: Implications for infant health. *Int Dairy J.* 2019;92:37–49.
3. Petit V, Sandoz L, Garcia-Rodenas CL. Importance of the regiospecific distribution of long-chain saturated fatty acids on gut comfort, fat and calcium absorption in infants. *Prostaglandins Leukot Essent Fat Acids.* 2017;121:40–51.

4. Kloek W, Vonk MM, Feitsma AL, Timmer CJAM. Application of the similarity index to evaluate fat composition and structure in infant formulas. *Int Dairy J.* 2020;111:104834.
5. Manios Y, Karaglani E, Thijs-Verhoeven I, Vlachopapadopoulou E, Papazoglou A, Maragoudaki E, et al. Effect of milk fat-based infant formulae on stool fatty acid soaps and calcium excretion in healthy term infants: two double-blind randomised cross-over trials. *BMC Nutr.* 2020;6(1):1–10.
6. Wang L, Bravo-Ruiseco G, Happe R, He T, Dijl JM, Harmsen HJM. The effect of calcium palmitate on bacteria associated with infant gut microbiota. *Microbiologyopen.* 2021;10(3):1–11.
7. Yaron S, Shachar D, Abramas L, Riskin A, Bader D, Litmanovitz I, et al. Effect of high β -palmitate content in infant formula on the intestinal microbiota of term infants. *J Pediatr Gastroenterol Nutr.* 2013;56(4):376–81.
8. Yao M, Lien EL, Capeding MRZ, Fitzgerald M, Ramanujam K, Yuhas R, et al. Effects of term infant formulas containing high sn-2 palmitate with and without oligofructose on stool composition, stool characteristics, and bifidogenicity. *J Pediatr Gastroenterol Nutr.* 2014;59(4):440–8.
9. Wu W, Zhao A, Liu B, Ye WH, Su HW, Li J, et al. Neurodevelopmental outcomes and gut bifidobacteria in term infants fed an infant formula containing high Sn-2 palmitate: A cluster randomized clinical trial. *Nutrients.* 2021;13(2):1–14.
10. Beghini F, McIver LJ, Blanco-Míguez A, Dubois L, Asnicar F, Maharjan S, et al. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with biobakery 3. *Elife.* 2021;10:1–42.
11. McMurdie PJ, Holmes S. Phyloseq: An R package for reproducible interactive analysis and graphics of microbiome census data. *PLoS One.* 2013;8(4).
12. Van Tilburg MAL, Rouster A, Silver D, Pellegrini G, Gao J, Hyman PE. Development and validation of a Rome III functional gastrointestinal disorders questionnaire for infants and toddlers. *J Pediatr Gastroenterol Nutr.* 2016;62(3):384–6.
13. Ghanma A, Puttemans K, Deneyer M, Benninga MA, Vandenplas Y. Amsterdam infant stool scale is more useful for assessing children who have not been toilet trained than Bristol stool scale. *Acta Paediatr Int J Paediatr.* 2014;103(2):2013–4.
14. Breiman L. Random Forests. *Mach Learn.* 2001;45:5–32.
15. Liaw A, Wiener M. Classification and regression by randomforest. *R News.* 2002;2(3):18–22.
16. Bäckhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, et al. Dynamics and stabilization of the human gut microbiome during the first year of life. *Cell Host Microbe.* 2015;17(5):690–703.
17. Matsuki T, Yahagi K, Mori H, Matsumoto H, Hara T, Tajima S, et al. A key genetic factor for fucosyllactose utilization affects infant gut microbiota development. *Nat Commun.* 2016;7:1–12.
18. Lindmark Månsson H. Fatty acids in bovine milk fat. *Food Nutr Res.* 2008;52:1–3.
19. Nowacki J, Lee HC, Lien R, Cheng SW, Li ST, Yao M, et al. Stool fatty acid soaps, stool consistency and gastrointestinal tolerance in term infants fed infant formulas containing high sn-2 palmitate

- with or without oligofructose: A double-blind, randomized clinical trial. *Nutr J.* 2014;13(1):1–11.
20. Vork L, Penders J, Jalanka J, Bojic S, van Kuijk SMJ, Salonen A, et al. Does day-to-day variability in stool consistency link to the fecal microbiota composition? *Front Cell Infect Microbiol.* 2021;11:1–10.
 21. Vandeputte D, Falony G, Vieira-Silva S, Tito RY, Joossens M, Raes J. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. *Gut.* 2016;65(1):57–62.
 22. Macfarlane GT, Steed H, Macfarlane S. Bacterial metabolism and health-related effects of galacto-oligosaccharides and other prebiotics. *J Appl Microbiol.* 2008;104(2):305–44.
 23. Borewicz K, Suarez-Diez M, Hechler C, Beijers R, de Weerth C, Arts I, et al. The effect of prebiotic fortified infant formulas on microbiota composition and dynamics in early life. *Sci Rep.* 2019;9(1):1–13.
 24. Lee H, Slupsky CM, Heckmann AB, Christensen B, Peng Y, Li X, et al. Milk Fat Globule Membrane as a Modulator of Infant Metabolism and Gut Microbiota: A Formula Supplement Narrowing the Metabolic Differences between Breastfed and Formula-Fed Infants. *Mol Nutr Food Res.* 2020;2000603:1–10.
 25. He X, Parenti M, Grip T, Lönnerdal B, Timby N, Domellöf M, et al. Fecal microbiome and metabolome of infants fed bovine MFGM supplemented formula or standard formula with breast-fed infants as reference: a randomized controlled trial. *Sci Rep.* 2019;9(1):1–14.
 26. van den Elsen LWJ, Garssen J, Burcelin R, Verhasselt V. Shaping the gut microbiota by breastfeeding: The gateway to allergy prevention? *Front Pediatr.* 2019;7:1–10.
 27. Chen J, Li H, Hird SM, Chen MH, Xu W, Maas K, et al. Sex differences in gut microbial development of preterm infant twins in early life: A longitudinal analysis. *Front Cell Infect Microbiol.* 2021;11:1–16.
 28. Kim YS, Unno T, Kim BY, Park MS. Sex differences in gut microbiota. *World J Mens Health.* 2020;38(1):48–60.
 29. Warensjö E, Smedman A, Stegmayr B, Hallmans G, Weinehall L, Vessby B, et al. Stroke and plasma markers of milk fat intake - A prospective nested case-control study. *Nutr J.* 2009;8(1):1–7.
 30. Taormina VM, Unger AL, Schiksnis MR, Torres-Gonzalez M, Kraft J. Branched-chain fatty acids—an underexplored class of dairy-derived fatty acids. *Nutrients.* 2020;12(9):1–16.
 31. Liu L, Wang Z, Park HG, Xu C, Lawrence P, Su X, et al. Human fetal intestinal epithelial cells metabolize and incorporate branched chain fatty acids in a structure specific manner. *Prostaglandins Leukot Essent Fat Acids.* 2017;116:32–9.
 32. Yan Y, Wang Z, Greenwald J, Kothapalli KSD, Park HG, Liu R, et al. BCFA suppresses LPS induced IL-8 mRNA expression in human intestinal epithelial cells. *Prostaglandins Leukot Essent Fat Acids.* 2017;116:27–31.
 33. Nunes E, Rafacho A. Implications of palmitoleic acid (palmitoleate) on glucose homeostasis, insulin resistance and diabetes. *Curr Drug Targets.* 2016;18(6):619–28.

34. Zeb A. A comprehensive review on different classes of polyphenolic compounds present in edible oils. *Food Res Int.* 2021;143:110312.
35. Strandwitz P, Kim KH, Terekhova D, Liu JK, Sharma A, Levering J, et al. GABA-modulating bacteria of the human gut microbiota. *Nat Microbiol.* 2019 Mar 10;4(3):396–403.
36. Altaib H, Nakamura K, Abe M, Badr Y, Yanase E, Nomura I, et al. Differences in the concentration of the fecal neurotransmitters GABA and glutamate are associated with microbial composition among healthy human subjects. *Microorganisms.* 2021;9(2):1–15.
37. Yunes RA, Poluektova EU, Dyachkova MS, Klimina KM, Kovtun AS, Averina O V., et al. GABA production and structure of gadB/gadC genes in *Lactobacillus* and *Bifidobacterium* strains from human microbiota. *Anaerobe.* 2016;42:197–204.
38. Brink LR, Mercer KE, Piccolo BD, Chintapalli S V., Elolimy A, Bowlin AK, et al. Neonatal diet alters fecal microbiota and metabolome profiles at different ages in infants fed breast milk or formula. *Am J Clin Nutr.* 2020;111(6):1190–202.
39. Sillner N, Walker A, Lucio M, Maier T V., Bazanella M, Rychlik M, et al. Longitudinal profiles of dietary and microbial metabolites in formula- and breastfed infants. *Front Mol Biosci.* 2021;8:1–14.
40. Chow J, Panasevich MR, Alexander D, Vester Boler BM, Rossoni Serao MC, Faber TA, et al. Fecal metabolomics of healthy breast-fed versus formula-fed infants before and during in vitro batch culture fermentation. *J Proteome Res.* 2014;13(5):2534–42.
41. Berger B, Porta N, Foata F, Grathwohl D, Delley M, Moine D, et al. Linking human milk oligosaccharides, infant fecal community types, and later risk to require antibiotics. *MBio.* 2020;11(2):1–18.

Figures

Figure 1

Study flowchart

VF: standard formula with 100% vegetable fat source; MF: test formula with 50% milk fat.

Figure 2

Relative abundance of bacterial genera in the three faecal samples for each of the subjects.

VF: standard formula with 100% vegetable fat source; MF: test formula with 50% milk fat

Figure 3

Multi-dimensional scaling (MDS) plot based on Bray-Curtis dissimilarity measures of the faecal microbial species.

Figure 4

Individual palmitic acid soap values by intervention in milligrams palmitic acid soap per gram faeces.

VF: Standard formula with 100% vegetable fat source; MF: test formula with 50% milk fat

Figure 5

Distribution of the stool consistency categories of the Amsterdam Infant Stool Scale scores per intervention.

VF: standard formula with 100% vegetable fat source; MF: test formula with 50% milk fat

Figure 6

Volcano plot of measured faecal metabolites.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Additionalfile1Supplementarytablesandfigure.pdf](#)
- [Additionalfile2RawdatametabolomicsEffectbovinemilkfatbasedinfantformulae.xlsx](#)